Viking Therapeutics Stock Stages Impressive Recovery

Industry Consolidation Fuels Optimism

Viking Therapeutics shares registered substantial double-digit gains late last week, propelled by favorable sector developments and sustained bullish sentiment among Wall Street analysts.

The biopharmaceutical company’s stock surged 12.78% on Thursday, maintaining strong momentum with elevated trading volumes through Friday’s session. Although shares closed slightly lower at $25.40 (down 2.46%), this minor pullback followed significant prior-day gains and substantial early trading advances.

Recent merger and acquisition activity within the biotechnology sector served as the primary catalyst for renewed investor interest. Roche’s acquisition announcement of MASH-focused 89bio generated positive reverberations throughout the industry. Viking Therapeutics stands to benefit from this increased attention given its own MASH candidate, VK2809.